alexa Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Gastroenterology

Gastroenterology

Journal of Liver

Author(s): Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL,

Abstract Share this page

Abstract PURPOSE: Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC). Our multinational, randomized, double-blind, phase III trial compared brivanib with sorafenib as first-line treatment for HCC. PATIENTS AND METHODS: Advanced HCC patients who had no prior systemic therapy were randomly assigned (ratio, 1:1) to receive sorafenib 400 mg twice daily orally (n = 578) or brivanib 800 mg once daily orally (n = 577). Primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), disease control rate (DCR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), and safety. RESULTS: The primary end point of OS noninferiority for brivanib versus sorafenib in the per-protocol population (n = 1,150) was not met (hazard ratio [HR], 1.06; 95.8\% CI, 0.93 to 1.22), based on the prespecified margin (upper CI limit for HR ≤ 1.08). Median OS was 9.9 months for sorafenib and 9.5 months for brivanib. TTP, ORR, and DCR were similar between the study arms. Most frequent grade 3/4 adverse events for sorafenib and brivanib were hyponatremia (9\% and 23\%, respectively), AST elevation (17\% and 14\%), fatigue (7\% and 15\%), hand-foot-skin reaction (15\% and 2\%), and hypertension (5\% and 13\%). Discontinuation as a result of adverse events was 33\% for sorafenib and 43\% for brivanib; rates for dose reduction were 50\% and 49\%, respectively. CONCLUSION: Our study did not meet its primary end point of OS noninferiority for brivanib versus sorafenib. However, both agents had similar antitumor activity, based on secondary efficacy end points. Brivanib had an acceptable safety profile, but was less well-tolerated than sorafenib. TRIAL REGISTRATION: ClinicalTrials.gov NCT00858871. This article was published in J Clin Oncol and referenced in Journal of Liver

Relevant Expert PPTs

Relevant Speaker PPTs

  • Li Yu-Jung
    Intra-maxillary Drug delivery and Bio-sensing via Dental Implant and its considerations
    PPT Version | PDF Version
  • Nicolae Bacalbasa
    The benefits of surgery for breast cancer liver metastases – a single center experience
    PPT Version | PDF Version
  • Sitanshu Sekhar Lahiri
    A novel oral formulation for cancer therapy, loaded in a slow release matrix for targeted delivery
    PPT Version | PDF Version
  • Li-Chun Tsou
    Drug delivery device strategy for patient centric therapies
    PDF Version
  • Dipesh Shah
    Compatibility assessment of a model monoclonal antibody formulation in glass and in blow-fi ll-seal (BFS) plastic vial delivery formats
    PPT Version | PDF Version
  • Stephanie Ramos
    Enhanced Delivery of Dna-Based Vaccines and Immunotherapeutics through Next-Generation Electroporation Devices
    PPT Version | PDF Version
  • Nirmala Chauhan
    Modification of dietary fiber psyllium for use in oral insulin delivery
    PPT Version | PDF Version
  • Youngmi Jung
    TSG-6 induces liver regeneration by enhancing autophagy in mice with chronic liver damage
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Suoqin Tang
    Survivin siRNA nano particles are capable of inhibiting liver cancer cell growth both in vitro and in vivo
    PPT Version | PDF Version
  • Arshad mahmood
    TRANSPORT OF SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM (SNEDDS) ACROSS MUCUS AND CELLULAR INTERNALIZATION
    PPT Version | PDF Version
  • Wei Duan
    Cancer stem cells targeted delivery of siRNA to overcome induced chemoresistance
    PPT Version | PDF Version
  • Yung-Chih Kuo
    “Yung-Chih Kuo-National-Chung-Cheng-University-Republic-of-China-Targeting-delivery-of-etoposide-to-inhibit-the-growth-of-human-glioblastoma-multiforme-using-lactoferrin-and-folic-acid-grafted-poly(lactide-co-glycolide)-nanoparticles”
    PPT Version | PDF Version
  • Biplab Mishra
    Compression of hepatoduodenal ligament by sponges during perihepatic packing for liver trauma leading to difficult maneuvering of angiography catheter through common hepatic artery: ‘Mishra Phenomenon’
    PPT Version | PDF Version
  • Mukesh Kumar
    Membrane fusion mediated cytosolic drug delivery through scFv targeted Sendai viral envelopes
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords